Rationale and study design of the OISTER trial: Optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes - A comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation

Journal of Cardiovascular Medicine

Volumn 11, Issue 7, 2010, Pages 536-543

  Iaccarino, Daniele ^a   Politi, Luigi ^a   Rossi, Rosario ^a   Sgura, Fabio ^a   Monopoli, Daniel ^a   Modena, Maria Grazia ^a   Sangiorgi, Giuseppe M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

DES; Endothelium; Optical coherence tomography; Paclitaxel; Re endothelialization; Restenosis; Trapidil

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GLYCERYL TRINITRATE; HEPARIN; PACLITAXEL; TRAPIDIL; VASCULOTROPIN; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; ANGIOGRAPHY; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; REVIEW; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VASODILATATION; VASOMOTOR REFLEX; ANGIOCARDIOGRAPHY; BLOOD; CELL PROLIFERATION; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; DRUG EFFECTS; HEART CATHETERIZATION; ITALY; LONGITUDINAL STUDY; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PROSTHESIS; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CARDIAC CATHETERIZATION; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HUMANS; ITALY; LONGITUDINAL STUDIES; PACLITAXEL; PROSTHESIS DESIGN; RESEARCH DESIGN; SINGLE-BLIND METHOD; THROMBOSIS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TRAPIDIL; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953262896     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32833499c4     Document Type: Review

References (36)

1. Raff GL, O'Neill WW. Interventional therapy of the acute coronary syndromes. Prog Cardiovasc Dis 2002; 44:455-468.
2. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol 2007; 100:3K-9K.
3. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007; 116:1952-1965.
4. King SB 3rd. Applying drug-eluting stents in clinical practice. Am J Cardiol 2007; 100:25K-31K.
5. Melfi R, Nusca A, Patti G, Di Sciascio G. The risks and benefits of drugeluting stents in the setting of STEMI. Curr Cardiol Rep 2008; 10:402-406.
6. Ryan J, Cutlip DE, Cohen DJ, Pinto DS. Drug eluting stents for ST-elevation myocardial infarction: risk and benefit. J Thromb Thrombolysis 2007; 24:293-299.
7. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. baremetal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28:2706-2713. (Pubitemid 350139205)
8. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008; 51:23-32.
9. Silber S. When are drug-eluting stents effective? A critical analysis of the presently available data. Z Kardiol 2004; 93:649-663.
10. Abbott JD, Voss MR, Nakamura M, Cohen HA, Selzer F, Kip KE, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007; 50:2029-2036.
11. Stähli BE, Camici GG, Tanner FC. Drug-eluting stent thrombosis. Ther Adv Cardiovasc Dis 2009; 3:45-52.
12. Iakovou I, Schmidt T, Bonizzoni E, Sangiorgi GM, Stankovic G, Airoldi F, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126-2130.
13. Aytekin V, Erdim R, Gormez S, Demiroglu C. Very late thrombosis of paclitaxel-eluting stent. Cardiovasc Revasc Med 2008; 9:275-277.
14. Tamburino C, Ussia GP, Zimarino M, Galassi A, De Caterina R. Early restenosis after drug-eluting stent implantation: a putative role for platelet activation. Can J Cardiol 2007; 23:57-59.
15. Gurbel PA, DiChiara J, Tantry US. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am J Cardiol 2007; 100:18M-25M.
16. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115:1051-1058.
17. Muhlestein JB. Endothelial dysfunction associated with drug-eluting stents what, where, when, and how? J Am Coll Cardiol 2008; 51:2139-2140.
18. Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K, et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007; 48:553-567.
19. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46:231-236. (Pubitemid 40966848)
20. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 2007; 71:220-225.
21. Khan M, Mhullain FN, Nolan M. Intrepide; trapidil eluting stent. Eurointervention 2008; 4:405-411.
22. Hoshiya M, Awazu M. Trapidil inhibits platelet-derived growth factorstimulated mitogen-activated protein kinase cascade. Hypertension 1998; 31:665-671.
23. Cirillo P, Golino P, Ragni M, Battaglia C, Pacifico F, Formisano S, et al. Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovasc Res 1999; 43:210-218.
24. Liu MW, Roubin GS, Robinson KA, Black AJ, Hearn JA, Siegel RJ, King SB 3rd. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 1990; 81:1089-1093.
25. Zacharowski K, Schneidmüller D, Ibe W, Grosser T, Buerke M, Meyer J, Darius H. Effects of local delivery of Trapidil on neointima formation in a rabbit angioplasty model. Br J Pharmacol 2000; 129:566-572.
26. Poon M, Cohen J, Siddiqui Z, Fallon JT, Taubman MB. Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits. Lab Invest 1999; 79:1369-1375.
27. Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123:1439-1444.
28. Nishikawa H, Ono N, Motoyasu M. Preventive effect of trapidil (PDGF antagonist)onrestenosis afterPTCA.Circulation1992;86(SupplIII):1-53.
29. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation 1994; 90:2710-2715.
30. Galassi AR, Tamburino C, Nicosia A, Russo G, Grassi R, Monaco A, Giuffrida G. A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheter Cardiovasc Interv 1999; 46:162-168.
31. Serruys PW, Foley DP, Pieper MK, Leijne JA, de Feyter PJ, TRAPIST investigators. The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Eur Heart J 2001; 22:1938-1947.
32. Elliot J, Maclassac A. Destiny 1 clinical trial: a first in man clinical evaluation of the icon trapidil eluting stent. Am J Cardiol 2005; 96:210.
33. Khana MM, Hanifb B, Hassanb K, Ahmadc F, Soomrod K, Majeede M, et al. Patient apt study: patients treated with the intrepide trapidil-eluting stent on a reduced antiplatelet therapy: medium-term outcome in diabetic and nondiabetic patients. Cardiovasc Revasc Med 2008; 9:120.
34. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C. Incomplete stent apposition and very late stent thrombosis after drugeluting stent implantation. Circulation 2007; 115:2426-2434.
35. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, et al., NOBORI CORE Investigators. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008; 51:2123-2129.
36. Tanigawa J, Barlis P, Di Mario C. Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition. Eurointervention 2007; 3:128-136.